🆕 As a part of Project NextGen, we opened a new area of interest (AOI 15) under our Broad Agency Announcement (BAA), seeking submissions for the clinical development & efficacy of phase 2-ready next generation #COVID19 vaccines. https://t.co/AoytHSsrk2
$MRK $MRNA neoantigen immunotherapy mRNA-4157 (mostly) lives up to its billing in adjuvant melanoma. Now on to phase 3. Via @evaluatevantage from #AACR23 -> https://t.co/S4SLFuBQBQ
"We already have the ability to generate vaccines that might provide more durable, variant-proof immunity, and this is to develop vaccines that contain conserved genes or gene regions that can act as targets for CD8+ T cells. https://t.co/theKTKLYTf
Looking forward to being a part of this panel discussion today where we'll talk about fostering a positive and inclusive company culture within a start-up environment. Register: https://t.co/d7Zy2VNyqD #inclusion#DEI#culture
#samRNA continues to deliver! Excited to see what value this platform can continue to unlock - more durable immunity is needed across viral pathogens (#SARSCoV2 and beyond)
Dr. Larry Corey of Fred Hutch and the Hutch-based @HelpEndHIV & @PreventCOVID_19 is the recipient of this year's Alexander Fleming Award. Corey is recognized by his peers for his lifetime achievements against infectious diseases. #IDWeek2022@IDSAInfo https://t.co/z8kCSPk9bG
Following our poster at #IDweek2022, we'll be hosting a webcast on 10/25/2022 at 8am ET to share new data from our CORAL - program - a great example of the potential broad application of our #samRNA platform in infectious diseases. #mrna#mrnavaccines#saRNA
Weekend reading: what's coming up in neoantigen immunotherapy after $MRK $MRNA buy-in? Via @evaluatevantage https://t.co/348P7PAiHs $ACHL $GRTS $JNJ $TCRT $BNTX